Maldonado R, Girdlestone D, Roques B P
Unité de Pharmacochimie Moléculaire, U 266 INSERM, UA 498 CNRS, Université René Descartes, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France.
Neurosci Lett. 1993 Jun 25;156(1-2):135-40. doi: 10.1016/0304-3940(93)90457-v.
In order to clarify the participation of substance P in the expression of opiate withdrawal, we have investigated the effects induced by the new selective neurokinin-1 antagonist RP 67580 on naloxone-induced morphine withdrawal syndrome in rats. Intracerebroventricular administration of RP 67580 elicited a decrease in 7 of the 13 withdrawal signs evaluated. Mastication, salivation and signs related to the motor component of withdrawal (jumping, rearing and locomotor activity) were particularly reduced. One sign, wet dog shakes, was increased, but it was also enhanced by the inactive enantiomer RP 68651. Our results indicate that blockade of NK1 receptors induces a decrease in the expression of naloxone-precipitated morphine abstinence in rats, and support the participation of substance P in the opiate withdrawal response.
为了阐明P物质在阿片类药物戒断反应中的作用,我们研究了新型选择性神经激肽-1拮抗剂RP 67580对大鼠纳洛酮诱发的吗啡戒断综合征的影响。脑室内注射RP 67580可使所评估的13种戒断症状中的7种症状减轻。咀嚼、流涎以及与戒断运动成分相关的症状(跳跃、竖毛和运动活动)尤其减轻。有一项症状,即湿狗样抖动增加,但无活性对映体RP 68651也可增强该症状。我们的结果表明,阻断NK1受体可使大鼠纳洛酮诱发的吗啡戒断反应减轻,支持P物质参与阿片类药物戒断反应。